Efficacy by specific cytogenetic abnormality at baseline (high-risk subgroup)
| . | High-risk subgroup . | |||
|---|---|---|---|---|
| Cytogenetic abnormality . | t(4;14) Only . | del(17p) Only in ≥60% of plasma cells . | ||
| . | KRd (n = 30) . | Rd (n = 25) . | KRd (n = 13) . | Rd (n = 13) . |
| PFS, median mo | 23.1 | 16.7 | 24.5 | 11.1 |
| ORR, n (%)* | 24 (80.0) | 18 (72.0) | 10 (76.9) | 6 (46.2) |
| . | High-risk subgroup . | |||
|---|---|---|---|---|
| Cytogenetic abnormality . | t(4;14) Only . | del(17p) Only in ≥60% of plasma cells . | ||
| . | KRd (n = 30) . | Rd (n = 25) . | KRd (n = 13) . | Rd (n = 13) . |
| PFS, median mo | 23.1 | 16.7 | 24.5 | 11.1 |
| ORR, n (%)* | 24 (80.0) | 18 (72.0) | 10 (76.9) | 6 (46.2) |
Determined by Independent Review Committee according to International Myeloma Working Group Uniform Response Criteria. Patients evaluated for ORR had a best overall response of partial response or better.